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ABSTRACT 
BACKGROUND: Menopausal Hormone Therapy (MHT) increases breast cancer risk, 
however, most cohort studies omit MHT use after enrolment and many infer menopausal 
age. 
METHODS: We used information from serial questionnaires from the UK Generations 
Study cohort to estimate hazard ratios (HRs) for breast cancer among post-menopausal 
women with known menopausal age, and examined biases induced when not updating 
data on MHT use and including women with inferred menopausal age. 
RESULTS: Among women recruited 2003–2009, at six years follow-up, 58,148 had 
reached menopause and 96% had completed a follow-up questionnaire.  Among 39,183 
women with known menopausal age, 775 developed breast cancer, and the HR in 
relation to current estrogen plus progestogen (E+P) MHT use (based on 52 current E+P 
MHT users in breast cancer cases) relative to those with no previous MHT use was 2.74 
(95% confidence interval (CI): 2.05–3.65) for a median duration of 5.4 years current use, 
reaching 3.27 (95% CI: 1.53–6.99) at 15+ years use.  The excess HR was underestimated 
by 53% if E+P MHT use was not updated after recruitment, 13% if women with masked 
uncertain menopausal age were included, and 59% if both applied.  The HR for estrogen-
only MHT was not raised (HR=1.00; 95% CI: 0.66–1.54). 
CONCLUSION: Lack of updating MHT status through follow-up and inclusion of women 
with inferred menopausal age is likely to result in substantial underestimation of the 
excess relative risks for E+P MHT use in studies with long follow-up, limited updating of 
exposures, and changing or short durations of use. 
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Menopausal hormone therapy (MHT) provides effective relief from climacteric symptoms 
but some are associated with increased risk of stroke, venous thromboembolism, and 
breast, ovarian, and endometrial cancers (Medicines and Healthcare Products Regulatory 
Agency UK, 2007; Santen et al, 2010).  MHT prescribing decreased rapidly (Ameye et al, 
2014) after its adverse effects on risk of breast cancer were highlighted in reports from 
the Women’s Health Initiative trial (Rossouw et al, 2002) and the Million Women Study 
(Beral & Million Women Study, 2003), but nevertheless it continues to be used by many 
women worldwide (Antoine et al, 2016; Chlebowski & Anderson, 2012). 
Accurate information about the risks (and benefits) of MHT is essential to allow 
women to make informed decisions about their health, and evidence from observational 
studies is important because it is no longer justifiable to conduct long term trials of MHT 
safety (Vickers et al, 2007).  There are, however, shortfalls in the way information has 
been collected and analysed in most published epidemiological studies (Bakken et al, 
2004; Bakken et al, 2011; Beral & Million Women Study, 2003; Beral et al, 2011; Brinton 
et al, 2008; Calvocoressi et al, 2012; Chen et al, 2004; Chen et al, 2006; Colditz et al, 
1995; Cordina-Duverger et al, 2013; Daling et al, 2002; Fournier et al, 2005; Fournier et al, 
2014; Li et al, 2003; Li et al, 2000; Magnusson et al, 1999; Newcomb et al, 2002; Nyante 
et al, 2013; Ritte et al, 2012; Roman et al, 2016; Saxena et al, 2010; Schairer et al, 2000; 
Stahlberg et al, 2004; Thorbjarnardottir et al, 2014).  In prospective studies that only 
collect information on MHT up to the time of recruitment (e.g. cohort studies with no 
follow-up questionnaires) current use of MHT and duration of use may be misclassified 
because some never-users of MHT will become users during follow-up, and some users 
will become ex-users; this may lead to biased assessment of breast cancer risk in relation 
to MHT use (Lee et al, 2005; Van Leeuwen & Rookus, 2003) but the extent has not been 
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assessed empirically.  Additionally, analyses that include women who have had simple 
hysterectomy (i.e. without oophorectomy) before natural menopause will also lead to 
biased results (Collaborative Group on Hormonal Factors in Breast Cancer, 1997; Pike et 
al, 1998; Rockhill et al, 2000; Simpson et al, 2007) but many case-control and cohort 
studies include such women (Bakken et al, 2004; Bakken et al, 2011; Beral & Million 
Women Study, 2003; Beral et al, 2011; Brinton et al, 2008; Calvocoressi et al, 2012; Chen 
et al, 2004; Chen et al, 2006; Colditz et al, 1995; Cordina-Duverger et al, 2013; Daling et 
al, 2002; Fournier et al, 2005; Fournier et al, 2014; Li et al, 2003; Li et al, 2000; 
Magnusson et al, 1999; Newcomb et al, 2002; Ritte et al, 2012; Roman et al, 2016; 
Saxena et al, 2010; Schairer et al, 2000; Stahlberg et al, 2004; Thorbjarnardottir et al, 
2014).  Thus while the epidemiological evidence clearly shows a raised risk of breast 
cancer with MHT use (Campagnoli et al, 2005; Greiser et al, 2005; Lee et al, 2005), there 
is uncertainty about the magnitude of the risk. 
To address these issues we used serial questionnaire information from the 
Breakthrough Generations Study (BGS), which has ascertained MHT use and menopausal 
status at entry and during prospective follow-up, to estimate the relative risk of breast 
cancer in relation to MHT use among women whose age at menopause was known.  We 
also assessed the likely extent of the biases that occur when only baseline questionnaire 
information is available and if women with simple hysterectomy are included in analyses.  
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MATERIALS AND METHODS 
The Breakthrough Generations Study (BGS) is a cohort study of 113,693 women from the 
United Kingdom (UK), aged 16 or older, from whom questionnaire information and 
informed consent was gained at recruitment during 2003–2015.  The first follow-up 
questionnaire was completed at 2½ years after recruitment, a second at approximately 
six years, and a third at 9½ years.  The study was approved by the South East Multi-
Centre Research Ethics Committee. 
Breast and other cancers occurring in the cohort were identified from recruitment 
and follow-up questionnaires and spontaneous reports to the study centre.  Confirmation 
of diagnosis was obtained from the cancer registries in the United Kingdom, ‘flagging’ at 
the National Health Service Central Registers (virtually complete registers of the 
populations of England and Wales, and of Scotland, to which study participants can be 
linked and on which deaths and cancer registrations are ‘flagged’ and then periodically 
reported to authorized medical researchers), pathology reports, and correspondence 
with patients’ general practitioners. 
Information on MHT was obtained at recruitment and from the second follow-up 
questionnaire, and was used to assess MHT exposure from menopause to date of breast 
cancer incidence or end of follow-up.  Women were asked the ages or years they started 
and stopped episodes of MHT use, whether they were still using MHT, and the name of 
each drug used.  We also asked participants at recruitment and in the second follow-up 
questionnaire how old they were when their periods stopped completely (i.e. they had 
gone six months without having had a period).  Women who could not report age at 
natural menopause, because of hysterectomy without bi-lateral oophorectomy or 
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because they were taking MHT or oral contraceptives around the time of menopause (i.e. 
at least six months without having a period and not being pregnant), were excluded from 
the main analyses because it was not possible to determine the age at which their 
ovarian function ceased.  Information was also collected on other breast cancer risk 
factors (Swerdlow et al, 2011). 
Statistical analysis 
The current analytic cohort is based on all women who were recruited to the study during 
June 2003–December 2009 inclusive without previous breast cancer.  The recruitment 
cut-off at December 2009 was selected because at the time of analysis the follow-up for 
the second questionnaire was practically complete for this group of recruits.  Women 
with known age at menopause entered risk at their date of recruitment or menopause, 
whichever was later, and were censored at the earliest date of: first invasive or in-situ 
breast cancer; death; follow-up questionnaire; or loss to study follow-up.  Left-truncated 
and right censored Cox proportional hazards regression (Cox, 1972) using attained age as 
the implicit time scale was used to estimate hazard ratios (HR) and 95% confidence 
intervals (CI) for MHT use and risk of first invasive or in-situ breast cancer, adjusted for 
(continuous) menopausal age. 
MHT was analysed as a time-varying exposure lagged by one year (Fournier et al, 
2005; Schairer et al, 2000).  The effect of the lag was to make the year following start of 
treatment a non-exposed period (as the exposure within the early months of use is 
unlikely to be the cause of breast cancers occurring in that period), and the year after 
cessation to be considered a part of the period of exposure, which avoided a potential 
‘reverse causation’ bias, since MHT may be stopped during work-up to a formal breast 
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cancer diagnosis.  Follow-up time for each woman was divided into the period(s), after 
onset of menopause, that were: before MHT use, current MHT use, and after cessation of 
MHT use.  A woman could move from being a user to ex-user to user again if there was a 
gap of at least one year between periods of MHT use (reports of MHT ending and re-
starting within one year were treated as contiguous periods of use).  In sensitivity 
analyses exploring the effect of not updating MHT use beyond baseline we assumed a 
duration of use as recorded at baseline and did not extrapolate the duration of use 
beyond that reported at baseline. 
Drug preparation was assigned based on the type of MHT used longest during 
each contiguous episode of use.  Tests for trend in duration of current use were 
calculated over periods of 0–<1, 1–<2, ... years, scored as 0.5, 1.5, ..., and included an 
indicator variable for current-user versus never-user (i.e. never-users were not treated as 
users with zero duration but as a separate category, to allow for systematic differences 
between those who are prescribed MHT and those who are not).  Heterogeneity in HRs 
for sub-types of breast cancer by behaviour, estrogen receptor status, and morphology, 
was assessed using a data augmentation method (Lunn & McNeil, 1995).  To assess 
potential confounding in addition to that due to age at menopause (as a continuous 
variable) we also adjusted for: birth cohort; benign breast disease; family history of 
breast cancer in 1st degree relatives; socio-economic score; age at menarche; age at first 
pregnancy and parity; duration of breastfeeding; oral contraceptive use before 
menopause; alcohol consumption; physical activity; pre-menopausal body mass index at 
age 20 years (BMI); and post-menopausal BMI at recruitment (or if unavailable, from 
second follow-up questionnaire).  We included any breast cancers diagnosed after 
recruitment (i.e. no minimum interval) but adjusted for, and tested for heterogeneity in,  
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time since recruitment to BGS cohort (<1 year; 1+ year).  We carried out additional 
analyses including women with uncertain menopausal age by including follow-up from 
these women only from age 58 (the age by which 99% of women with known 
menopausal age were post-menopausal) but, to allow adjustment for menopausal age 
and estimation of duration of MHT use since menopause, we assumed menopause 
occurred at age 50 years (and only considered MHT use if it was used from this age).  All 
statistical tests were two-sided and analyses were conducted using Stata/IC version 14.0 
(StataCorp, 2015).  
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RESULTS 
During 2003–2009 a recruitment questionnaire was completed by 104,164 women who 
joined the BGS without prior breast cancer (or mastectomy), of whom 58,148 were 
established as post-menopausal before the censoring date for analysis.  The first follow-
up questionnaire at 2½ years after recruitment was completed by 57,592 of these women 
(99.0%) and the second follow-up questionnaire at approximately six years after 
recruitment was completed by 55,923 (96.2%) of these post-menopausal women (3.7% 
completed an abridged version by telephone).  Of the remainder at second follow-up, 
1.2% had died by this time, 1.7% were alive but had not completed the questionnaire 
although their vital and cancer status was available from ‘flagging’ at the National Health 
Service Central Registers, and 0.9% were lost to follow-up at an earlier date (e.g. 
emigrations) or no follow up was available.  The follow-up rate (calculated as the total 
observed person-years divided by the person-years that would have been achievable if all 
post-menopausal women were followed-up to their second questionnaire or, if earlier, 
death) was 99.5%. 
Menopausal age was known for 39,183 women and was uncertain (i.e. by 
hysterectomy, MHT or oral contraceptive use) for 18,965.  Of those with known 
menopausal age 88.9% reported a natural menopause and 9.4 % reported bilateral 
oophorectomy as the reason for menopause; the remaining 1.7% reported various other 
procedures or treatments.  The median interval between menopause and subsequent 
recruitment for the 30,113 women known to be post-menopausal at recruitment was 7 
years (interquartile range: 3 to 13 years).  There were 9070 women pre-menopausal at 
recruitment who subsequently became post-menopausal during follow-up and at that 
point became eligible for analysis (median interval between recruitment and incident 
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menopause for these 9070 women: 4 years; interquartile range: 2 to 5 years).  The 
following results, unless otherwise stated, are based on the women with known 
menopausal age.  The mean menopausal age was 50.2 (standard deviation: 4.6) years and 
mean postmenopausal BMI was 25.7 (standard deviation: 4.5) kg/m2.  Table 1 presents 
further descriptive characteristics of the cohort and the pattern of MHT use at 
recruitment: 5.0% of women who had not used MHT by recruitment subsequently used 
MHT sometime during follow-up and 65.4% of current users at recruitment ceased use by 
end of follow-up.  At recruitment the median duration of use of estrogen-only MHT was 
6.5 years (interquartile range: 2.5 to 10.5 years), of estrogen plus progestogen MHT was 
5.5 years (interquartile range: 2.5 to 9.5 years), and was 4.5.years (interquartile range: 
1.5 to 8.5 years) for other types of MHT.  Supplementary Table 1 describes the 775 first 
incident invasive or in-situ breast cancers that were diagnosed during 204,390 person-
years (median 6.0 years) follow-up among 39,183 women with known age at menopause 
(and similar descriptive statistics for 18,965 women with unknown age at menopause). 
The HR for invasive and in-situ breast cancer adjusted for menopausal and 
attained age was 1.95 (95% CI: 1.55–2.46; P<0.001) for current users of all types of MHT 
relative to never users (Table 2).  The HR increased with duration of current use by 3.8% 
per year (95% CI: 0.4%–7.3%; P=0.027) and at 15+ years was 2.02 (95% CI: 1.12–3.66; 
P=0.020).  There was little difference in HR and trend after adjusting for further potential 
confounding variables (results shown in Supplementary Table 2; distribution of 
adjustment variables in Supplementary Tables 3 and 4) so the following results adjust 
only for menopausal and attained age.  Risk was not significantly raised for past MHT use 
overall or by type of MHT preparation (Table 2), or estrogen receptor status (Table 3), or 
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morphological type (Supplementary Table 5), nor did the HR in past users differ by 
duration of past use (<5 years versus 5+ years: Pheterogeneity=0.093). 
Analysed by type of MHT preparation (Table 2), for estrogen-only preparations 
(median duration of current use 6.6 years) breast cancer risk was not significantly 
increased with current use (HR=1.00; 95% CI: 0.66–1.54; P=0.99) and there was a non-
significant increase in HR per year of use (4.2% per year of use; 95% CI: −1.8%–10.5%; 
P=0.17).  For combined estrogen plus progestogen preparations (median duration of 
current use 5.4 years) there was a significantly raised risk with current use compared with 
never-use (HR=2.74; 95% CI: 2.05–3.65; P<0.001), and HR increased by 5.6% (95% CI: 
1.2%–10.2%; P=0.011) per year of use, reaching HR=3.27 (95% CI: 1.53–6.99; P=0.002) at 
15+ years of use.  As can be seen by the non-overlapping confidence intervals there was a 
significant difference between the HRs for breast cancer risk in relation to current 
estrogen-only MHT use versus never use compared to current estrogen plus progestogen 
use versus never use (Pheterogeneity<0.001).  There was no heterogeneity by time since 
recruitment for risk of breast cancer in relation to estrogen only MHT use 
(Pheterogeneity=0.35) or combined MHT use (Pheterogeneity=0.72).  Without adjustment for 
menopausal age the HR for breast cancer and combined estrogen plus progestogen MHT 
use was 2.64 (95% CI: 1.98–3.52; P<0.001). 
The HR for combined estrogen plus progestogen preparations was 2.96 (95% CI: 
2.19–3.99; P<0.001) for invasive and 1.46 (95% CI: 0.53–4.00; P=0.47) for in-situ breast 
cancer, but the difference between these was not significant (Pheterogeneity=0.18) and in-situ 
breast cancer only accounted for 14% of cases (Supplementary Table 6 presents results 
for invasive breast cancer only).  HRs for combined MHT for ductal (HR=2.60; 95% CI: 
1.86–3.64; P<0.001) and lobular (HR=3.12; 95% CI: 1.50–6.51; P=0.002) breast cancers 
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were both raised but not significantly different to each other (Pheterogeneity=0.60) 
(Supplementary Table 5).  The HR for estrogen receptor positive breast cancer was 2.89 
(95% CI: 2.09–4.00; P<0.001) and was not significantly different to that for estrogen 
receptor negative breast cancer (Pheterogeneity=0.31) (Table 3). 
When analysed by type of combined estrogen plus progestogen MHT the HR for 
breast cancer for serial combined preparations (HR=2.95; 95% CI: 1.92–4.53; P<0.001) 
was not significantly different from that for continuous combined preparations (HR=2.67; 
95% CI: 1.82–3.95; P<0.001) (Pheterogeneity=0.74).  For other or unspecified types of MHT, of 
which tibolone use made up 49%, risk compared with never users was significantly 
increased with current use (P<0.001), but there was no significant trend with duration of 
use (P=0.78).  The HR for breast cancer for current tibolone use was 2.32 (95% CI: 1.03–
5.20; P=0.041).  Among women with no family history of breast cancer the HR for current 
tibolone use was 1.60 (95% CI: 0.51–4.99; P=0.42) but this was based on only three cases 
of breast cancer, and  among those with a positive family history of breast cancer the HR 
was 4.15 (95% CI: 1.32–13.1; P=0.015) but again was based on only three cases of breast 
cancer, and the difference between the HRs was not significant (P=0.25). 
The above analyses update data on MHT use after recruitment using serial 
questionnaire information and exclude women with uncertain menopausal age (e.g. 
because of hysterectomy).  We next examined the potential biases when these analytic 
procedures were not done (Table 4).  The number of women available for analysis was 
reduced when using baseline information only because women who become post-
menopausal after recruitment were not considered eligible, and the number of women 
available increased when those with uncertain menopausal age were included although 
their follow-up for risk of breast cancer only started at age 58 years  (only 13,404 women 
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with uncertain menopausal age reached this age during follow-up; descriptive statistics in 
Supplementary Tables 3 and 4).  The excess HR for breast cancer for combined MHT use 
was 53% smaller when usage during follow-up was ignored, 13% smaller when women 
with uncertain menopausal age were included in analyses, and 59% smaller for both 
these analytic approaches combined.  If restricted to invasive breast cancer only, the 
biases were 46%, 15%, and 56% respectively.  Table 4 also shows results by duration of 
use; at each duration there was about 50% bias when usage during follow-up was 
ignored. 
The interrelation between MHT, BMI and risk of breast cancer is shown in Table 5.  
Risk of breast cancer increased significantly (P<0.001) with greater BMI among women 
not using MHT and among past users (P=0.030).  The risk of breast cancer was increased 
with current use of combined estrogen plus progestogen MHT within each category of 
BMI but there was no significant trend with BMI (P=0.39 0.51).  The relative increase in 
risk for of combined estrogen plus progestogen MHT was smaller with greater BMI, for 
example, for BMI at 30+kg/m2, the HR was (3.40/1.64=) 2.07 (95% CI: 0.84–5.10; P=0.11), 
BMI at 25–<30kg/m2 the HR was (3.49/1.36=) 2.56 (95% CI: 1.53–4.27), and for 
BMI<25kg/m2 it was 3.27 (95% CI: 2.24–4.78; P<0.001) although the confidence intervals 
overlapped and the trend with BMI was not significantly different to the trend among 
never users of MHT (Pheterogeneity=0.79).  
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DISCUSSION 
In our cohort, the risk of post-menopausal breast cancer was increased with current use 
of MHT, as in previous studies (Anderson et al, 2012; Bakken et al, 2011; Beral et al, 2011; 
Campagnoli et al, 2005; Chlebowski & Anderson, 2012; Colditz et al, 1995; Collaborative 
Group on Hormonal Factors in Breast Cancer, 1997; Salagame et al, 2011; Santen et al, 
2010; Stahlberg et al, 2004), and the increase in risk was larger with combined estrogen 
plus progestogen than with estrogen only formulations, again as seen before (Bakken et 
al, 2011; Beral et al, 2011; Campagnoli et al, 2005; Chlebowski & Anderson, 2012; Colditz 
et al, 1995; Olsson et al, 2003; Roman et al, 2016; Stahlberg et al, 2004).  In particular, 
our relative risk estimates for current use of combined MHT are compatible with the 
results from epidemiological studies that have updated MHT use by questionnaire (Beral 
et al, 2011; Calle et al, 2009; Chen et al, 2004; Fournier et al, 2014) or record linkage 
(Roman et al, 2016).  Relative risk increased with greater duration of current combined 
MHT use, to 3.27 at 15+ years of use, and these long term risks were larger than those 
previously reported (Brinton et al, 2008; Li et al, 2003; Saxena et al, 2010), although there 
is considerable overlap in the confidence intervals around these estimates. 
We also found the association between risk of breast cancer and combined MHT 
use was compatible with previous publications which have shown attenuation of MHT-
associated breast cancer risks in women with high BMI relative to non-users of MHT with 
similar BMI (Beral et al, 2011; Ritte et al, 2012); consequently care is needed when 
comparing results between studies if they differ in BMI profile.  Our results, however, 
should be comparable with other large epidemiological studies in this respect since the 
average post-menopausal BMI of women in our study (25.7 kg/m2) was similar to that in 
the Million Women Study (Beral et al, 2011) (26.2 kg/m2), the European Prospective 
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Investigation into Cancer and Nutrition (Ritte et al, 2012) (24.8 kg/m2), and the Nurses’ 
Health Study (Kotsopoulos et al, 2010) (24.9 kg/m2), although notably lower than in the 
Women’s Health Initiative trial (Rossouw et al, 2002) (28.5 kg/m2).  However, our results 
for women with BMI 25–<30 kg/m2 (HR=2.56; 95% CI: 1.53–4.27) can be compared to the 
Women’s Health Initiative trial and observational study results for women who began 
combined MHT use within five years of menopause (HR=1.64; 95% CI: 1.00–2.68) 
(Prentice et al, 2008); our HR is larger but the confidence intervals from both studies 
overlap. 
We included invasive and in-situ breast cancer as the analysis endpoint, similar to 
the Million Women Study (Beral et al, 2011), although when we re-analysed using only 
invasive breast cancer as the endpoint we saw modestly larger relative risks, but this did 
not materially change our conclusions.  (For direct comparability with studies that only 
include invasive breast cancer these results are available in Supplementary Table 6). 
Previous studies have found greater risks for estrogen receptor positive than 
negative breast cancer (Chen et al, 2004; Fournier et al, 2008; Li et al, 2003) and we also 
saw the same for combined MHT use although the difference in risks in our study was not 
statistically significant perhaps because there were few current users of MHT who 
developed estrogen receptor negative breast cancer and with 775 cases of breast cancer 
and only 52 cases currently using combined MHT the study lacked power to detect such 
statistical interactions.  Our information on estrogen receptor status also has some 
limitations because it came from cancer registration reports and the cut-offs used to 
define positive/negative were not standardized beyond that used in routine practice.  We 
did not find overall raised risks stronger with combined continuous regimens than 
sequential ones, which is consistent with studies from the UK and USA (Beral & Million 
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Women Study, 2003; Brinton et al, 2008; Campagnoli et al, 2005; Li et al, 2003; Opatrny 
et al, 2008), although studies from northern Europe have tended to show higher rates for 
continuous relative to sequential regimens (Bakken et al, 2011; Campagnoli et al, 2005; 
Olsson et al, 2003; Roman et al, 2016; Stahlberg et al, 2004) and the disparity may be due 
to differences in progestogen monthly dose (Bakken et al, 2004; Campagnoli et al, 2005; 
Roman et al, 2016; Stahlberg et al, 2004).  The most frequently used serial regimens in 
our study were Prempak-C (conjugated estrogen, 625mcg, 1.25mg; norgestrel, 150mcg), 
Elleste Duet (estradiol, 1mg, 2mg; norethisterone, 1mg), and Climagest (Estradiol, 2mg; 
norethisterone, 1mg), and the most frequently used continuous regimens were Premique 
(conjugated estrogen, 625mcg; medroxyprogesterone acetate, 5mg), Kilovance (estradiol, 
1mg; norethisterone, 500mcg), and Kilofem (estradiol, 2mg; norethisterone, 1mg). 
  We found significantly increased risk with other or unspecified types of MHT.  
There was, however, no significant trend with duration of use in this group, perhaps 
because the increased risk may be a characteristic of women who take these other types 
of preparation rather than an effect of the preparation itself.  The most common type of 
MHT in this group was tibolone, a selective tissue estrogenic activity regulator, and 
evidence suggests that in the UK it is preferentially prescribed to women at increased risk 
of breast cancer (Wierik et al, 2007). 
Our MHT exposure information was gained at recruitment and from follow-up 
questionnaire six years later.  Since 96% of women completed this follow-up it seems 
unlikely that misclassification of exposure in the remaining 4% would have materially 
influenced our results.  Some of our MHT usage was collected after diagnosis of breast 
cancer and this has potential to introduce recall bias.  If women with breast cancer were 
more motivated to recall past exposures we may expect to have seen raised risks for 
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estrogen only MHT and combined MHT separately but the hazard ratio for estrogen only 
MHT use was not raised.  However, given the attention combined MHT has received in 
the lay press women with breast cancer may preferentially recall combined MHT use.  But 
we note that only 10 out of the 52 women diagnosed with breast cancer, and who were 
current users of combined MHT, first started MHT use after recruitment to the study and 
the other 42 reported current use at recruitment, before their breast cancer diagnosis.  It 
therefore seems unlikely that our results are appreciably affected by recall bias.  Follow-
up for vital and breast cancer status was obtained for 99% of participants and 
confirmation of reported breast cancers for 98%, so there was little scope for biases from 
unascertained mortality or exits, or erroneous reporting of breast cancer.  A large 
proportion of women were excluded from our main analysis because their age at 
menopause was uncertain or unknown, usually because they started MHT or had 
hysterectomy without oophorectomy, before cessation of menstrual bleeding.  A benefit 
gained by their exclusion is that our analysis was not diluted by the inclusion of possibly 
mis-classified pre-menopausal women.  Furthermore the exclusion of women with 
unknown age at menopause does not produce biased results in prospective studies 
because these women could legitimately not have been recruited to a cohort if they were 
deemed ineligible by protocol, however, as a consequence our results may be less 
generalizable to all post-menopausal women.  This lack of generalizability also affects 
other studies that have considered it inappropriate to include these women in their main 
analyses of MHT and breast cancer risk (Collaborative Group on Hormonal Factors in 
Breast Cancer, 1997; Pike et al, 1998; Rosenberg et al, 2006; Ross et al, 2000). 
There are potential biases in cohort studies that only collect information on 
history of MHT use up to the time of recruitment (e.g. with no follow-up exposure data) 
06/07/2016 
 
 Page 21 of 30 
 
which can seriously misclassify actual use (Lee et al, 2005; Van Leeuwen & Rookus, 2003).  
Magnitude of effect in randomized controlled trials may also suffer from bias due to 
misclassification of exposure if adherence to treatment is not complete.  For example, in 
the Women’s Health Initiative trial of combined MHT 42% of women in the active 
treatment arm discontinued MHT, and 10.7% of women in the placebo arm started MHT, 
at some point during the active intervention (Rossouw et al, 2002). 
By using information from follow-up questionnaires we were able to update MHT 
status, and duration, right up to the breast cancer diagnosis or censoring date, and so 
avoid the misclassification that would occur if only baseline questionnaire information 
were available.  Without such follow-up information (i.e. as in many published cohorts 
(Bakken et al, 2004; Bakken et al, 2011; Beral & Million Women Study, 2003; Brinton et 
al, 2008; Nyante et al, 2013; Saxena et al, 2010; Stahlberg et al, 2004)) we found that the 
excess breast cancer risk for combined MHT would be under-estimated by around 53%.  
The Women’s Health Initiative randomized clinical trial saw a similar degree of under-
estimation in risk of breast cancer for estrogen plus progestogen treatment relative to 
placebo when comparing an analysis making allowance for non-adherence to MHT with 
an intention to treat analysis (49% increased risk of breast cancer versus a 24% increased 
risk; i.e. 51% reduction in excess relative risk) (Chlebowski & Anderson, 2012). 
Biases may also occur if analyses included women with simple hysterectomy 
before menopause (i.e. without oophorectomy) or who started MHT before cessation of 
menstrual bleeding (Collaborative Group on Hormonal Factors in Breast Cancer, 1997; 
Pike et al, 1998; Rockhill et al, 2000; Simpson et al, 2007), as most published cohort and 
case-control studies have done (Bakken et al, 2004; Bakken et al, 2011; Beral & Million 
Women Study, 2003; Beral et al, 2011; Brinton et al, 2008; Calvocoressi et al, 2012; Chen 
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et al, 2004; Chen et al, 2006; Colditz et al, 1995; Cordina-Duverger et al, 2013; Daling et 
al, 2002; Fournier et al, 2005; Fournier et al, 2014; Li et al, 2003; Li et al, 2000; 
Magnusson et al, 1999; Newcomb et al, 2002; Ritte et al, 2012; Roman et al, 2016; 
Saxena et al, 2010; Schairer et al, 2000; Stahlberg et al, 2004; Thorbjarnardottir et al, 
2014).  We found that the consequent under-estimation of the excess HR for combined 
MHT use, because of not adjusting adequately for menopausal age, was around 13%.  
However, women with simple hysterectomy, or those who started MHT before cessation 
of menstrual bleeding, may be different to women with known age at menopause, and 
this could be responsible for some or all of the bias. 
For the combination of both the above types of bias we found that excess breast 
cancer risks would be underestimated by 59%.  However the uncertainty around this 
estimate is large (we estimate 35%–83%), and furthermore study-specific characteristics 
(e.g. when study was conducted, duration of follow-up, etc.) are also likely to affect the 
size of bias that might be seen in other studies.  The misclassification of current use of 
MHT may be less important in older studies conducted before results were published 
from the Women’s Health Initiative trial (Rossouw et al, 2002) and Million Women Study 
(Beral & Million Women Study, 2003) since following these reports women stopped using 
MHT in large numbers (Ameye et al, 2014; Chlebowski & Anderson, 2012).  However, 
current advice suggests women should use MHT for the shortest possible time (Stuenkel 
et al, 2015) thus observational studies conducted post 2002/03 should be cautious about 
assuming MHT use at baseline will continue for the duration of the study. 
A number of cohort studies have reported relative risks for breast cancer around 
2.0 to 2.5 for 10 or more years combined MHT use (Bakken et al, 2011; Beral & Million 
Women Study, 2003; Brinton et al, 2008; Santen et al, 2010; Saxena et al, 2010), but this 
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is presumably an underestimate because all of these studies did not update MHT use 
through follow-up and included in analyses women with uncertain menopausal age.  If 
correction is made for the bias this induces we estimate the relative risk would be in the 
range 2.7 to 3.5, which is similar to the 3.5 we observed for 10+ years use.  However, at 
shorter durations of use too we saw appreciable bias and underestimation of the relative 
risk for combined MHT use. 
In conclusion, our results show that risk of breast cancer increases with duration 
of use of combined MHT up to 15 and more years, and relative risks in most of the 
published literature are likely to be substantially underestimated because of lack of 
updating MHT status through follow-up in cohort studies and inclusion of women with 
inferred menopausal age in cohort or case-control analyses.  These results provide 
further information to allow women to make informed decisions about the potential risks 
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Study population
N % N %
Year of birth
1908–1939 4303 11.0 2111 11.1
1940–1949 14626 37.3 7922 41.8
1950–1959 16692 42.6 6775 35.7
1960–1985 3562 9.1 2157 11.4
2003–2004 890 2.3 13 0.1
2005–2006 17060 43.5 910 4.8
2007–2008 12567 32.1 3101 16.4
2009–2015 8666 22.1 9380 49.5
Not included in analytic follow-up 0 0.0 5561 29.3
22–44 890 2.3 0 0.0
45–54 14430 36.8 0 0.0
55–64 18033 46.0 7824 41.3
65–74 5051 12.9 4939 26.0
75–98 779 2.0 641 3.4
Not included in analytic follow-up 0 0.0 5561 29.3
None reported 32614 83.2 16019 84.5
Yes 6569 16.8 2946 15.5
None reported 29455 75.2 13752 72.5
Yes 9728 24.8 5213 27.5
7–11 8091 20.7 4177 22.0
12–14 23665 60.4 11122 58.6
15–19 3806 9.7 1784 9.4
Not known 3621 9.2 1882 9.9
Parity
Nulliparous 5404 13.8 2110 11.1
Parous 33724 86.1 16825 88.7
Not known 55 0.1 30 0.2
None reported 7576 19.3 3385 17.9
Previous use 31607 80.7 15580 82.2
No previous use 20114 66.8 5414 36.2
Ex-user 5771 19.2 5495 36.7
Current user: estrogen only 1719 5.7 1905 12.7
Current user: estrogen plus progestogen 1612 5.4 1491 10.0
Current user: other or unspecified MHT 398 1.3 211 1.4
Dates used unknown 499 1.7 440 2.9
Total number of subjects 39183 100.0 18965 100.0
Women with 
unknown age at 
menopause
TABLE 1. Characteristics of women from the Breakthrough Generations Study who were recruited 
2003–2009 and became post-menopausal before end of follow-up
a Start of analytic follow-up based on latest of recruitment date or date became post-menopausal, or for 
women with unknown age at menopause, date became aged 58
b Excludes women premenopausal at recruitment (9070 among those with known menopausal age; 
4009 among those with unknown menopausal age)
Year of entry to analytic follow-upa
Age at start of analytic follow-up (years)a
Family history of breast cancer in 1st degree relative
History of benign breast disease
Age at menarche (years)
Oral contraceptive use
Post-menopausal MHT use at recruitmentb















No previous use 500 1.00 Baseline
Currently using 23 1.00 0.66–1.54 52 2.74 2.05–3.65 15 3.04 1.81–5.33 90 1.95 1.55–2.46
 >0–4 7 0.80 0.38–1.69 14 1.71 1.00–2.92 29 1.50 1.03–2.19
5–9 6 0.96 0.43–2.16 19 3.53 2.23–5.60 29 2.29 1.57–3.34
10–14 6 1.41 0.62–3.17 12 3.70 2.07–6.04 20 2.49 1.57–3.92
15+ 4 1.14 0.42–3.08 7 3.27 1.53–6.99 12 2.02 1.12–3.66
4.2% −1.8%–10.5% 5.6% 1.2%–10.2% 1.3% −7.6%–11.1% 3.8% 0.4%–7.3%
Past use 44 0.96 0.70–1.31 99 1.02 0.82–1.28 29 0.81 0.55–1.18 172 0.97 0.81–1.16
1 2 0.40 0.10–1.62 10 1.61 0.86–3.01 12 0.92 0.52–1.63
2–4 18 1.02 0.63–1.63 30 1.09 0.76–1.59 52 0.99 0.74–1.32
5–9 17 0.99 0.61–1.62 33 0.80 0.56–1.15 14 1.06 0.62–1.82 64 0.89 0.68–1.17
10+ 7 1.35 0.63–2.86 26 1.30 0.86–1.95 11 0.88 0.48–1.62 44 1.17 0.84–1.62
2.1% −6.7%–11.8% −1.0% −6.9%–5.2% 1.4% −6.8%–10.3%
Dates of use 
unknown ‡
0 2 1.95 0.49–7.83 11 1.26 0.69–2.30 13 1.23 0.71–2.13
} 8 2.96 1.47–5.97
Currently using MHT: by duration of current use (years)c
Baseline group: No previous useb
TABLE 2. Relative riska of (invasive and in-situ ) post-menopausal breast cancer, by type of MHT preparation, in relation to MHT duration and recency of use, in 39,183 women from the Breakthrough 
Generations Study who were recruited 2003–2009
Type of MHT preparation
All types of MHT
Estrogen only Estrogen plus Progestogen Other and unknown MHT
Abbreviations: CI, Confidence Interval;  HR, Hazard Ratio, adjusted for attained age and age at menopause; MHT, menopausal hormone therapy
a Hazard ratios estimated using Cox proportional hazards regression with attained age as time scale
3.12 1.48–6.60
Past use of MHT: by time since last use (years)e
} 4 0.42 0.16–1.11
Increase in HR per year since last use amongst past users (trend) f
Increase in HR per year of use amongst current users (trend) d
} 7
f Trend and intercept fitted for past users relative to hazard in those with no previous use (person-time for current use and missing dates when MHT used are excluded from trend analysis)
b Baseline group is ‘No previous use’ as in analysis for ‘All types of MHT’
c Duration of MHT current use was analysed as a time-varying exposure lagged by one year
d Trend and intercept fitted for current users relative to hazard in those when no previous use (person-time for past use and missing dates when MHT used are excluded from trend analysis)











No previous use 374 1.00 Baseline 71 1.00 Baseline 55 1.00 Baseline
Currently using Estrogen only MHT 20 1.19 0.75–1.88 2 0.49 0.12–2.03 1 0.50 0.07–3.66
Currently using Estrogen plus Progestogen MHT 41 2.89 2.09–4.00 5 1.70 0.68–4.24 6 3.19 1.36–7.44
Currently using other and unknown MHT 12 3.30 1.85–5.87 3 3.83 1.20–12.28 0
Past use 128 0.94 0.76–1.16 27 1.01 0.63–1.62 17 1.11 0.63–1.97
Dates of use unknown 9 1.12 0.58–2.18 3 1.86 0.58–5.93 1 0.91 0.13–6.62
a Hazard ratios estimated using Cox proportional hazards regression with attained age as time scale
Abbreviations: CI, Confidence Interval ; HR, Hazard Ratio, adjusted for attained age and age at menopause; MHT, menopausal hormone therapy
TABLE 3. Relative riska of (invasive and in-situ ) post-menopausal breast cancer, by estrogen receptor status, in relation to MHT, in 39,183 women from the Breakthrough 
Generations Study who were recruited 2003–2009
Breast cancer estrogen receptor status







HR 95% CI Biasd
No. of 
cases
HR 95% CI Biasd
No. of 
cases
HR 95% CI Biasd
500 1.00 Baseline 525 1.00 Baseline 584 1.00 Baseline 531 1.00 Baseline
52 2.74 2.05–3.65 62 1.82 1.39–2.38 53% 73 2.51 1.96–3.21 13% 101 1.71 1.38–2.13 59%
1–4 14 1.71 1.00–2.92 22 1.32 0.86–2.02 56% 15 1.62 0.97–2.71 13% 30 1.26 0.87–1.82 63%
5–9 19 3.53 2.23–5.60 25 2.35 1.56–3.53 47% 26 2.91 1.95–4.33 25% 35 1.70 1.20–2.40 72%
10+ 19 3.54 2.21–5.65 15 2.34 1.38–3.97 47% 32 2.97 2.07–4.28 22% 36 2.51 1.77–3.55 40%
No updating of MHT use beyond baseline, 
women with uncertain menopausal age included
No previous use
Currently using
TABLE 4. Relative riska of (invasive and in-situ ) post-menopausal breast cancer, by duration of current use of estrogen plus progestogen MHT, for analyses with and without MHT updated through follow-up and inclusion or 
exclusion of women with uncertain menopausal age, in women from the Breakthrough Generations Study who were recruited 2003–2009
MHT use updated through follow-up, 
women with uncertain menopausal age 
excluded
No updating of MHT use beyond baseline, 
women with uncertain menopausal age excluded
MHT use updated through follow-up, women 
with uncertain menopausal age included
(Number of women=39,183) (Number of women=39,183) (Number of women=52,587) b (Number of women=43,484) b,c
Currently using  Estrogen Plus Progestogen MHT: by duration of current use (years)
e
Abbreviations: CI, Confidence Interval; HR, Hazard Ratio, adjusted for attained age and age at menopause; MHT, menopausal hormone therapy
a Hazard ratios estimated using Cox proportional hazards regression with attained age as time scale
d Bias in excess relative risk: ( (HR0-1)-(HR1-1) ) / (HR0-1) where HR0 is the HR estimated when MHT use is updated through follow-up and women with uncertain menopausal age excluded, and HR1 is the biased HR
e Duration of MHT use was lagged by one year in all analyses, and analysed as a time-varying exposure only when MHT use was updated through follow-up
b
 Women with uncertain age at menopause only contributed follow-up from age 58 years















No previous use 203 1.00 Baseline 188 1.36 1.12–1.66 100 1.64 1.29–2.08 1.04 1.02–1.06 <0.001 ---
Currently using Estrogen only MHT 16 1.52 0.91–2.54 1 0.17 0.02–1.21 5 2.25 0.92–5.52 0.97 0.90–1.05 0.51 0.17
Currently using Estrogen plus Progestogen MHT 31 3.27 2.24–4.78 16 3.49 2.10–5.82 5 3.40 1.40–8.26 1.03 0.96–1.12 0.39 0.79
Currently using other and unknown MHT 10 4.46 2.36–8.43 5 3.84 1.58–9.32 0 0.98 0.83–1.15 0.78 0.41
Past use 88 1.18 0.91–1.53 44 0.85 0.61–1.19 38 1.94 1.37–2.76 1.04 1.00–1.07 0.030 0.91
Dates of use unknown 7 1.50 0.71–3.19 6 2.04 0.91–4.61 0 0.93 0.80–1.09 0.39 0.18
TABLE 5. Relative riska of (invasive and in-situ ) post-menopausal breast cancer, in relation to MHT, by postmenopausal BMI in 39,183b women in the Breakthrough Generations Study who were recruited 2003–2009
c Trend
b 1041 women (2.7%) excluded from analysis because BMI was not known
a Hazard ratios estimated using Cox proportional hazards regression with attained age as time scale




<25 25–<30 30+ (HR per unit increase in BMI)
Trend
Breast cancer characteristic
N % N %
42–54 128 16.5 73 16.4
55–64 401 51.7 194 43.5
65–74 208 26.8 158 35.4
75–86 38 4.9 21 4.7
2004–2006 76 9.8 42 9.4
2007–2009 299 38.6 165 37.0
2010–2012 327 42.2 200 44.8
2013–2014 73 9.4 39 8.7
Invasive 670 86.4 373 83.6
Carcinoma in-situ 105 13.6 73 16.4
Confirmeda 761 98.2 440 98.7
Self-reported onlyb 14 1.8 6 1.4
Ductal 574 74.1 330 74.0
Medullary 3 0.4 0 0.0
Mucinous or colloid 7 0.9 4 0.9
Lobular 120 15.5 74 16.6
Tubular 13 1.7 6 1.4
Papillary 1 0.1 1 0.2
Type unknown 57 7.4 31 7.0
Positive 584 75.4 344 77.1
Negative 111 14.3 59 13.2
Type unknown 80 10.3 43 9.6
Total number of cases 775 100 446 100.0
Women with 
unknown age at 
menopause 
(n=18965)
SUPPLEMENTARY TABLE 1. Characteristics of incident (invasive and in-situ ) breast 
cancer cases arising in post-menopausal women from the Breakthrough Generations 
Study who were recruited 2003–2009
a Confirmation through national cancer registration or medical records
b With reported treatments that imply self-reported breast cancer is correct
Estrogen receptor status
Age at breast cancer diagnosis (years)
Year of breast cancer diagnosis
Type of breast cancer
Confirmation of breast cancer
Morphological type
Women with known 















No previous use 500 1.00 Baseline
Currently using 23 1.01 0.66–1.56 52 2.82 2.11–3.78 15 3.05 1.82–5.12 90 1.98 1.57–2.51
 >0–4 7 0.80 0.38–1.70 14 1.80 1.05–3.08 29 1.52 1.04–2.23
5–9 6 0.97 0.43–2.18 19 3.70 2.33–5.88 29 2.34 1.60–3.42
10–14 6 1.46 0.65–3.29 12 3.64 2.03–6.50 20 2.52 1.59–3.99
15+ 4 1.14 0.42–3.11 7 3.29 1.53–7.03 12 2.05 1.13–3.71
4.4% −1.6%–10.7% 5.6% 1.1%–10.2% 2.3% −6.7%–12.2% 4.0% 0.6%–7.5%
Past use 44 0.94 0.68–1.28 99 1.03 0.83–1.29 29 0.81 0.55–1.18 172 0.97 0.81–1.16
1 2 0.40 0.10–1.59 10 1.63 0.87–3.05 12 0.92 0.52–1.63
2–4 18 1.00 0.62–1.60 30 1.12 0.77–1.62 52 0.99 0.74–1.32
5–9 17 0.97 0.60–1.59 33 0.82 0.57–1.17 14 1.09 0.64–1.86 64 0.91 0.69–1.19
10+ 7 1.27 0.59–2.70 26 1.26 0.84–1.89 11 0.86 0.47–1.58 44 1.13 0.82–1.57
0.9% −8.0%–10.7% −2.2% −8.1%–4.1% 0.4% −7.8%–9.2%
Dates of use 
unknown ‡
0 2 2.07 0.51–8.33 11 1.21 0.67–2.20 13 1.19 0.69–2.07
d Trend and intercept fitted for current users relative to hazard in those when no previous use (person-time for past use and missing dates when MHT used are excluded from trend analysis)
e The period up to the first year after cessation is considered to be part of the period of current use because exposure (current use) is lagged by one year
} 4 0.42 1.16–1.12
Abbreviations: CI, Confidence Interval;  HR, Hazard Ratio, adjusted for attained age, age at menopause (continuous), and potential confounding variables (birth cohort (1908-39, 1940-44, 1945-49, 
1950-54, 1955-85), time since recruitment (<1 year, 1+ year), family history of breast cancer (yes, none reported), previous benign breast disease (yes, none reported), socio-economic status (high, 
low), age at menarche (continuous age, and categorical indicator variables for menarche age known or missing), parity and age at first birth and number of births and duration of breast-feeding 
(continuous age at first birth, number of pregnancies, continuous weeks breast-fed among those breast-feeding, and categorical indicator variable for nulliparous, parous but not breast feeding, 
parous and breast feeding, or unknown), oral contraceptive use (yes, none reported), alcohol consumption (continuous grams/day, and categorical indicator variable for never regular drinker, current 
drinker, ex-drinker, or missing/excessive (>60grams/day)), physical activity (continuous log(metabolic equivalents) and categorical indicator variable for known or missing), pre-menopausal body 
mass index (continuous kg/(m*m) and categorical indicator variable for known or missing), post-menopausal body mass index (continuous kg/(m*m) and categorical indicator variable for known or 
missing)); MHT, menopausal hormone therapy
a
 Hazard ratios estimated using Cox proportional hazards regression with attained age as time scale
Increase in HR per year since last use amongst past users (trend) f
3.25 1.53–6.88
Increase in HR per year of use amongst current users (trend) d
b Baseline group is ‘No previous use’ as in analysis for ‘All types of MHT’
c Duration of MHT current use was analysed as a time-varying exposure lagged by one year
f Trend and intercept fitted for past users relative to hazard in those with no previous use (person-time for current use and missing dates when MHT used are excluded from trend analysis)
SUPPLEMENTARY TABLE 2. Relative riska of (invasive and in-situ ) post-menopausal breast cancer adjusted for potential confounding variables, by type of MHT preparation, in relation to MHT 
duration and recency of use, in 39,183 women from the Breakthrough Generations Study who were recruited 2003–2009
Type of MHT preparation
All types of MHT
Estrogen only Estrogen plus Progestogen Other and unknown MHT
Past use of MHT: by time since last use (years)e
Baseline group: No previous useb
Currently using MHT: by duration of current use (years)c














1908–1939 105 25.3 68 12.3
1940–1944 129 31.3 106 19.2
1945–1949 248 55.8 123 26.6
1950–1954 160 50.6 31 8.5
1955–1985 133 41.3 1 0.2
0–<1 110 30.3 42 9.3
1+ 665 174.1 287 57.5
None reported 583 170.2 254 56.2
Yes 192 34.2 75 10.6
None reported 518 153.2 206 47.4
Yes 257 51.2 123 19.4
High 423 109.4 150 29.3
Low 352 95.0 179 37.5
Age at menarche
Known 705 186.1 303 60.6
Missing 70 18.3 26 6.2
Parity, age at first pregnancy, and breast-feeding
Nulliparous 111 28.4 33 6.3
Parous, no breast-feeding 89 22.4 40 9.6
Parous, with breast feeding 493 135.2 225 42.9
Missing 82 18.4 31 8.1
Yes 561 152.8 118 21.3
None reported 214 51.6 221 45.5
Alcohol consumption
Never regular 114 29.0 46 10.9
Current drinker 579 115.5 247 50.0
Ex-drinker 40 11.8 22 3.4
Missing or excessive (>60grams/day) 42 8.1 14 2.6
Known 760 198.2 315 64.0
Missing 15 6.2 14 2.8
Known 643 165.7 271 53.8
Missing 132 38.7 58 13.0
Known 763 200.1 327 65.8
Missing 12 4.3 2 1.1
Total 775 204.4 329 66.8
Women with known age at 
menopause, follow-up from 
latest of recruitment or 
menopause (n=39,183)
Women with unknown age at 
menopause, follow-up from 
age 58 (n=13,404)
SUPPLEMENTARY TABLE 3. Number of breast cancer cases and person-years of follow-up for women from the 
Breakthrough Generations Study who were recruited 2003–2009 and became post-menopausal before end of follow-
up: adjustment variables
Time since entry (years)
Family history of breast cancer in 1st degree relative


















Age at menarche (years) 35565 12.7 1.5 12151 12.7 1.5
Number of parous births, if parous 30210 2.27 0.82 10496 2.31 0.8
Age at first parous delivery (years) 30210 26.5 4.6 10496 25.1 4.2
Breast-feeding (weeks), if breast fed 26059 22.7 21.2 8622 18.0 17.7
Alcohol consumption (grams/day), if current drinker 29947 16.4 11.9 10012 16.6 12.0
Physical activity (metabolic equivalents) 38031 67.9 52.9 12867 70.5 55.0
Pre-menopausal BMI (kg/m
2
) 31896 21.3 2.6 10793 21.3 2.5
Post-menopausal BMI (kg/m2) 38142 25.7 4.5 13200 26.1 4.4
Age at menopause (years) 39183 50.2 4.6 13404 50.4 1.7
Women with known age at 
menopause, follow-up from latest of 
recruitment or menopause (n=39,183)
Women with unknown age at 
menopause, follow-up from age 
58 (n=13,404)
SUPPLEMENTARY TABLE 4. Means and standard deviations of continuous adjustment variables for women from the Breakthrough 











No previous use 373 1.00 Baseline 75 1.00 Baseline 52 1.00 Baseline
Currently using Estrogen only MHT 16 0.90 0.54–1.49 4 1.42 0.51–3.93 3 1.28 0.39–4.21
Currently using Estrogen plus Progestogen MHT 38 2.60 1.86–3.64 8 3.12 1.50–6.51 6 3.25 1.38–7.62
Currently using other and unknown MHT 12 3.17 1.78–5.64 2 3.04 0.74–12.4 1 2.02 0.28–14.7
Past use 128 0.95 0.77–1.18 26 0.97 0.61–1.54 18 1.01 0.58–1.78
Dates of use unknown 7 0.87 0.41–1.84 5 3.35 1.35–8.30 1 0.90 0.12–6.56
Abbreviations: MHT, menopausal hormone therapy; HR, Hazard Ratio, adjusted for attained age and age at menopause; CI, Confidence Interval
a Hazard ratios estimated using Cox proportional hazards regression with attained age as time scale
b Trend and intercept fitted for current users relative to hazard in those when no previous use (person-time for past use and missing dates used excluded from trend analysis)
SUPPLEMENTARY TABLE 5. Relative riska of (invasive and in-situ ) post-menopausal breast cancer, by histology, in relation to MHT, in 39,183 women from the Breakthrough 
Generations Study who were recruited 2003–2009
Breast cancer histology














No previous use 428 1.00 Baseline
Currently using 21 1.09 0.70–1.70 48 2.96 2.19–3.99 13 3.12 1.79–5.43 82 2.10 1.64–2.67
 >0–4 7 0.97 0.46–2.06 11 1.62 0.88–2.95 24 1.50 0.99–2.28
5–9 5 0.96 0.40–2.32 18 3.86 2.40–6.21 27 2.50 1.69–3.71
10–14 6 1.64 0.73–3.70 12 4.28 2.39–7.65 10 2.88 1.82–4.56
15+ 3 0.97 0.31–3.05 7 3.69 1.73–7.90 10 2.09 1.13–3.89
3.4% −2.8%–10.0% 6.2% 1.6%–10.9% 3.0% −6.2%–12.9% 4.1% 0.6%–7.8%
Past use 40 1.00 0.72–1.40 85 1.01 0.79–1.28 25 0.80 0.53–1.20 150 0.97 0.80–1.18
1 1 0.24 0.03–1.69 10 1.87 1.00–3.50 11 0.99 0.54–1.80
2–4 18 1.17 0.73–1.89 27 1.14 0.77–1.68 47 1.03 0.76–1.40
5–9 14 0.94 0.55–1.60 28 0.78 0.53–1.15 14 1.22 0.71–2.08 56 0.89 0.67–1.19
10+ 7 1.52 0.71–3.24 20 1.13 0.71–1.79 9 0.81 0.42–1.59 36 1.08 0.76–1.54
2.5% −6.7%–12.6% −2.6% −9.0%–4.2% 2.0% −6.7%–11.6%
Dates of use 
unknown ‡
0 1 1.12 0.16–7.96 9 1.19 0.62–2.31 10 1.09 0.58–2.05
f Trend and intercept fitted for past users relative to hazard in those with no previous use (person-time for current use and missing dates when MHT used are excluded from trend analysis)
b Baseline group is ‘No previous use’ as in analysis for ‘All types of MHT’
c Duration of MHT current use was analysed as a time-varying exposure lagged by one year
d Trend and intercept fitted for current users relative to hazard in those when no previous use (person-time for past use and missing dates when MHT used are excluded from trend analysis)
e The period up to the first year after cessation is considered to be part of the period of current use because exposure (current use) is lagged by one year
Abbreviations: CI, Confidence Interval;  HR, Hazard Ratio, adjusted for attained age and age at menopause; MHT, menopausal hormone therapy
a Hazard ratios estimated using Cox proportional hazards regression with attained age as time scale
3.60 1.70–7.63
Past use of MHT: by time since last use (years)e
} 2 0.24 0.06–0.97
Increase in HR per year since last use amongst past users (trend) f
Increase in HR per year of use amongst current users (trend) d
} 7
Baseline group: No previous useb
SUPPLEMENTARY TABLE 6. Relative riska of invasive post-menopausal breast cancer, by type of MHT preparation, in relation to MHT duration and recency of use, in 39,183 women from the 
Breakthrough Generations Study who were recruited 2003–2009
Type of MHT preparation
All types of MHT
Estrogen only Estrogen plus Progestogen Other and unknown MHT
} 6 2.69 1.20–6.04
Currently using MHT: by duration of current use (years)c
